Both EGFR and HER2 have been successfully targeted for cancer therapeutics including small molecule kinase inhibitors (such as gefitinib, erlotinib, and lapatinib) and therapeutic monoclonal antibodies (such as cetuximab, panitumumab, and trastuzumab) [2, 3, 5]. This evidence concerns the gene ERBB2 and cancer.